[Biological therapy in rheumatoid arthritis].
Rheumatoid arthritis is an autoimmune disease of unknown etiology. It represents a public health problem since it affects 2% of economically active population. Treatment with cytotoxic drugs has improved quality of life in these patients. However, a significant amount of patients do not respond or do not tolerate this treatment modality. Biotechnology advances have given rise to a new treatment approach known as biological therapy. This new approach has opened a new therapeutical perspective in these patients. The objective of this publication is to review the different aspects of biological therapy, as well as to inform the initial results of clinical trials in patients with rheumatoid arthritis.
Abraham Simón
J
J
abrahamsimon@mailcity.com
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D001324:Autoantigens / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D001691:Biological Therapy; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors; D016207:Cytokines / Q000627:therapeutic use; D003888:Desensitization, Immunologic; D005544:Forecasting; D015316:Genetic Therapy; D006801:Humans; D008954:Models, Biological; D018716:Molecular Mimicry; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D001324:Autoantigens; D015815:Cell Adhesion Molecules; D016207:Cytokines